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Abstract
Background: Ineffectiveness of BCG vaccine in controlling tuberculosis (TB) and co-infection of TB and HIV have turned TB into
a serious global threat. Therefore, the development of an alternative vaccine to BCG and/or antimycobacterial drugs is an urgent
need. Here, three chimeric DNA constructs consisting of Mtb32C-HBHA, Ag85a-Tb10.4, and Ag85a-cfp10 made in our previous studies
were co-administered to BALB/c mice to evaluate their immune responses using a prime-boost regimen in which the animals were
first immunized with BCG and then administered with DNA vaccines.
Methods: In order to evaluate the immunogenicity of three DNA constructs, the levels of several immunomodulatory cytokines
were measured in vaccinated mice. Thirty female BALB/c mice were divided into the following groups (n = 10): control (receiving
pcDNA 3.1+ intramuscularly), vaccine (receiving recombinant vectors intramuscularly), and vaccine-BCG (receiving BCG subcuta-
neously followed by recombinant vectors intramuscularly).
Results: The levels of IL-4, IL-12, TGF-β, IFN-γ, and IL-10 were higher in the immunized groups than in the control group (P < 0.05).
Besides, the levels of IL-12 and IFN-γ were much higher in the BCG-vaccine group than in the vaccine alone group. In the case of
IFN-γ, a significant difference was observed between the vaccine and BCG-vaccine groups at P < 0.001 while in the case of IL-12, the
difference was significant at P < 0.05. However, in the case of IL-10, IL-4, and TGF-β, the differences between the vaccine and BCG-
vaccine groups were not significant (P > 0.05).
Conclusions: Our results proved that using a chimeric DNA vaccine as a booster in the prime-boost strategy could significantly
enhance the efficacy of BCG. This study suggests that the use of such DNA vaccines encoding mycobacterial immunogenic antigens
as boosters enhances the efficacy of BCG.
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1. Background
The TB mortality rate is estimated at about 37% accord-
ing to the 2017 global tuberculosis (TB) report by the World
Health Organization (WHO) (1, 2). Bacillus Calmette-Guérin
(BCG) vaccine is the first vaccine against TB developed by
two French scientists in 1921. The BCG vaccine contains
weakened or attenuated forms of Mycobacterium bovis that
naturally causes TB in animals such as cows. The BCG vac-
cine gives protection against severe forms of the infection,
especially TB meningitis, but it is less effective against pul-
monary TB (3).
Heparin-binding haemagglutinin (HBHA) is a surface
adhesin that mediates the attachment of mycobacteria to
lung epithelial cells and extrapulmonary dissemination of
TB. The disruption of the hbha gene or coating surface of
mycobacteria with anti-HBHA antibodies could hinder the
dissemination and colonization of Mycobacterium tubercu-
losis (M. tuberculosis) in the spleen. Ag85a has a mycolyl-
transferase activity that participates in the biogenesis of
trehalose dimycolate (cord factor) and cell wall integrity
and is a part of secreted proteins in M. tuberculosis and the
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BCG culture filtrate. Due to the ability of this antigen in
T cell proliferation and IFN-γ induction, it is considered a
promising vaccine candidate (4, 5).
Cfp10 is a secretory protein and a virulence factor en-
coded by “region of difference 1” (RD1) of the M. tuberculo-
sis genome that is absent in all strains of BCG. This region
has a major role in the virulence properties of Mycobac-
terium bovis bacillus and seems to be an important target
for protective CD4+ T cells immunity. Tb10.4 belongs to
a low molecular weight protein of the ESAT6 family. The
Tb10.4 gene is highly conserved in the clinical isolates of
M. tuberculosis and it plays a significant role in mycobac-
terial pathogenesis. The expression of the Tb10.4 gene is
downregulated in the attenuated strain of M. tuberculo-
sis (H37Ra) compared to the wild strain (H37Rv). Previ-
ous studies on Tb10.4-based vaccines showed that Tb10.4 is
an ideal vaccine candidate (1). Mtb32C is a C-terminal do-
main of mtb32A protein with strong activity in stimulating
cytotoxic T cells (CTL). Many previous studies confirmed
that these antigens show strong activity in stimulating im-
mune responses, especially cell mediate immunity (the
most effective response against TB), but, up to date, there
is no study showing the effectiveness of these antigens to-
gether (6). Due to the global public health threat of TB and
insufficient protection of BCG, developing a new and more
effective vaccine candidate is desperately required.
Vaccine strategies that employ primary vaccinations of
BCG with subsequent inoculation of DNA constructs en-
coding immunodominant antigens have been reviewed
and all obtained results have shown the enhanced ac-
tivity of T cell-mediated responses (7). Besides, previ-
ous studies have confirmed that Th1 cytokines like IFN-γ
and IL-12 have a critical role in providing essential pro-
tection against M. tuberculosis infection. In contrast, Th2
cytokines like IL-4 and IL-10 have a suppressive effect.
Surveying different modulating cytokines is an appropri-
ate means to predict the potential stimulation of im-
mune responses by a designated vaccine. In this study,
three chimeric DNA vaccines containing the fusion genes
(Mtb32C-HBHA, Ag85a-CFP10, and Ag85a-Tb10.4) were ad-
ministered to BALB/c mice alone or in combination with
BCG to evaluate immune-modulating cytokines including
IL-4, IL-10, IL-12, TGF-β, and IFN-γ in order to investigate
their effects as boosters in increasing the efficacy of the
BCG vaccine as a prime vaccine (8, 9).
2. Methods
2.1. Mice
Thirty specific pathogen-free (SPF) female BALB/c mice
(6 - 8 weeks’ age, 25 g weight) were obtained from the Razi
Vaccine and Serum Research Institute (Mashhad, Iran). All
mice were maintained in the SPF environment and all pro-
cedures performed were in accordance with the ethical
policies of Mashhad University of Medical Sciences (ethics
code IR.MUMS.REC.1393.160) and the guidelines of the Insti-
tutional Animal Care and Use Committees (10).
2.2. Construction of Chimeric DNA Vaccines
All recombinant vectors used were constructed in
previous studies. In summary, the genome of Mycobac-
terium tuberculosis H37Rv strain was extracted and related
genes including Mtb32C, hbha, Tb10.4, Cfp10, and Ag85a
were isolated and cloned into the pCDNA3.1+ vector using
polymerase chain reaction (PCR). Finally, three DNA vac-
cines (pCDNA+-Mtb32C-HBHA, pCDNA+-Ag85a-Cfp10, and
pCDNA+-Ag85a-Tb10.4) were constructed and the purified
vectors were injected into the tibialis anterior muscle of
susceptible animals (11, 12). In our previous studies, each
recombinant vector was given to BALB/c mice in a prime-
boost manner but in this study, all of them were assembled
and used as a single vaccine (9, 13-15).
2.3. Immunogenicity of Chimeric DNA Vaccines
Thirty female BALB/c mice were divided into three
groups [empty vector (pCDNA3.1+) as the control group,
chimeric DNA vaccines as the vaccine group, and BCG plus
chimeric DNA vaccines as the BCG-vaccine group]. The BCG-
vaccine group was first vaccinated subcutaneously with
BCG (5 × 105 CFU in PBS) (Pasture institute, Iran) (16) and
then after one month, they were inoculated intramuscu-
larly with chimeric DNA vectors (100 µg in 300 µL of PBS)
three times at two-week intervals (12, 17). The control group
and the vaccine group were immunized intramuscularly
with pCDNA3.1+ and three chimeric DNA vaccines, respec-
tively, at a total concentration of 100µg three times at two-
week intervals (9, 12, 18).
2.4. Cytokine Analysis
Four weeks after the last immunization, eight mice
from each group were sacrificed. First, the spinal cord was
cut and then, the spleen was removed using sterile instru-
ments. Their splenocytes were isolated, plated (3 × 105
cells per well), and cultured in 24-well plates containing
RPMI-1640 medium enriched with 10% fetal calf serum and
1% penicillin and streptomycin (19). The cells were stimu-
lated with the BCG vaccine (2 × 104 CFU) for 72 hours. Af-
ter stimulation, the culture supernatants were gathered
and interleukin-12 (IL-12), IL-4, IL-10, TGF-β, and IFN-γ were
measured using ELISA kits (BD, Biosciences, San Jose, CA) ac-
cording to the manufacturer’s instructions (19). The limits
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of detection of ELISA were as follows: 15 pg/mL for IFN-γ, 15
pg/mL for IL-12p70, 4 pg/mL for IL-4, 30 pg/mL for IL-10, and
8 pg/mL for TGF-β.
2.5. Statistical Analysis
The data were presented as means and standard devi-
ations. Normality was evaluated using the Kolmogorov-
Smirnov test. The differences between groups were as-
sessed using the one-way ANOVA with P values of < 0.05
considered statistically significant.
3. Results
One month after the final immunization, the animals
were killed. Cytokine productions were assessed in the
stimulated culture supernatant using the ELISA method
(BD Biosciences). The levels of different cytokines in each
group are listed in Table 1. As shown in Figure 1 and Table
1, the levels of the measured cytokines were significantly
higher in the vaccine group and BCG-vaccine group than
in the control group (P < 0.05).
Splenic cells from mice immunized with the BCG-
vaccine had slightly higher levels of IL-4 (10.42± 1.8 pg/mL),
TGF-β (10.96± 2.8 pg/mL), and IL-10(999.74± 277.2 pg/mL)
secretion than those from mice only receiving DNA vac-
cines [IL-10 (759.46± 240.1 pg/mL), IL-4 (11.74± 2.8 pg/mL),
and TGF-β (8.43 ± 0.75 pg/mL)], but differences were not
significant (P > 0.05).
The levels of IFN-γ (555.5±43 pg/mL) and IL-12 (38.56±
16.05 pg/mL) in the BCG-vaccine group were much higher
than the levels in the vaccine group [IFN-γ (424.5 ± 78
pg/mL) and IL-12 (26.85± 17.15 pg/mL)] and the differences
were significant (P < 0.001 and P < 0.05, respectively).
4. Discussion
Tuberculosis remains the main cause of death in many
parts of the world. Reducing the prevalence rate of TB
worldwide is the main gold of WHO; hence, much research
is underway in this filed (20).
Several meta-analyses indicated that the efficacy of the
BCG vaccine, as the only vaccine available against TB, is just
50% (21, 22). However, BCG is very effective against miliary
disease and TB meningitis and confers partial resistance to
leprosy and Buruli ulcer (23). The BCG efficacy is very lim-
ited in preventing adult pulmonary TB and cannot be used
in immunosuppressed patients because of fatal dissemi-
nated infections that may occur. Keeping with these obser-
vations, the development of a more effective vaccine pro-
vides a useful solution to the TB threat (24).
In many endeavors, several vaccines, as primary vac-
cines to replace BCG or as boosters for BCG, have been eval-
uated, some entering clinical trials. Recent research has
been promising for TB control in the future (25). Generally,
a prime-boost strategy is a promising approach to induce
protective cellular immunity, as its effectiveness has been
previously confirmed in humans. Priming with BCG and
boosting with a DNA vaccine encoding multiple antigens
showed a broad stimulation in cytokines production and
led to high levels of T-cell immunity. This strategy has en-
tered clinical trials and it is an impressive way to stimulate
long-time immune responses against M. tuberculosis (24).
The most advantage of a DNA vaccine over other types of
vaccines is related to its capacity in stimulating antigen-
specific cytotoxic T lymphocyte (CTL) and long-term intro-
duction of phase-dependent or poorly expressed antigens
in BCG in order to improve the BCG vaccine (26).
T cell subsets play an important role in inhibiting TB in-
fection and obtaining the optimal protection by inducing
IFN-γ-secreting CD4+ Th1 cells. The best way of evaluating a
vaccine’s efficacy is to identify immunological parameters.
In this regard, the levels of several cytokines were assessed
in the present study. IFN-γ and IL-12 play a central role in
response to TB. Previous studies indicated that the disrup-
tion of IFN-γ and IL-12 genes caused extreme susceptibility
to intracellular pathogens such as mycobacteria (27). In-
deed, identifying the levels of IFN-γ and IL-12 is the most
widely used method for the recognition of immune re-
sponses following vaccination. The balance between Th1
(IFN-γ, IL-12) and Th2 cytokines (IL-10, IL-4) is likely to influ-
ence the vaccine outcome (28).
IL-10 has an inhibitory effect on Th1 cells and blocking
this cytokine facilitates the IL-12 production from mono-
cytes by neutralizing antibodies and increasing the pro-
duction of IFN-γ (29). Although IL-10 is a suppressive cy-
tokine, it has been shown that own T cells (CD4+ effector
T cells) (30) are an alternative source of IL-10 production;
thus in our study, the high levels of IL-10 cytokine may be
related to this issue (31, 32). Moreover, there is a body of
evidence indicating that IL-10 has immunostimulatory ef-
fects on CD8+ Tcell cells. IL-10 in the presence of low doses
of IL-2 promotes the proliferation of CD8+ T cells, which is
believed to be involved in the successful elimination of my-
cobacterial infection and long-lasting control of the infec-
tion (33, 34).
TGF-β is an anti-inflammatory cytokine, which
prevents the activation and proliferation of naïve
TCD4+/TCD8+ cells, yet it has a contradictory effect on
different cells. For instance, TCD4+ in the presence of
TGF-β cannot differentiate, but TCD8+ cells following their
activation produce TGF-β which induces its differentia-
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Table 1. The Levels of Cytokines in Spleen Cell Culture Supernatants Using ELISAa , b
Vaccination Groups IL-12p70, pg/mL IL-4, pg/mL IL-10, pg/mL IFN-γ, pg/mL TGF-β, pg/mL
Control 7.16±1.7 3.37±0.85 320.3±62.3 29.9±13 2.5±1.2
Vaccine 26.85±17.15 11.74±2.8 759.46±240.1 424.5±78 8.43±0.75
BCG-vaccine 38.56±16.05 10.42±1.8 999.74±277.2 555.5±43 10.96±2.8
aThe values were expressed as median± SD in pg/mL.
bOne month after the third injection, eight mice from each group were killed and their splenocytes were cultured in the presence of BCG antigens. The levels of cytokines

































































Figure 1. The analysis of stimulated splenocytes in culture supernatant for interferon-γ (IFN-γ), IL-12, IL-10, IL-4, and TGF-β cytokines production. The one-way ANOVA and
Kolmogorov-Smirnov tests were used to determine statistical significance (P < 0.05).
tion. In spite of the inhibitory effect of TGF-β on T cells,
recent studies have shown that in certain circumstances,
TGF-β facilitates the growth of Th17 cells as the main effec-
tor cell in secreting IFN-γ and activating macrophages (35,
36).
In the present study, mice were primarily vaccinated
with BCG and then inoculated with three chimeric DNA
vaccines, leading to high levels of IL-12 and IFN-γ produc-
tion. These results demonstrate that the administration
of such regimen leads to a significant increase in cell-
mediated immune responses. In this work, the level of IL-4
as a Th2 biomarker was low, indicating that humoral im-
mune responses were not effectively stimulated. The ele-
vation of IL-12 along with TGF-β supports memory T cells
generation and their maintenance. The administration of
such DNA vaccines encoding Ag85a, HBHA, Mtb32C, cfp10,
and Tb10.4 antigens can improve the efficacy of the BCG
vaccine with a prime-boost strategy, as they are absent
or poorly expressed in BCG (37, 38). Many studies have
indicated that any mutation or disruption in the IFN- γ
gene or its receptors increases susceptibility to intracellu-
lar pathogens such as mycobacteria. Cytokine analysis in
our previous studies and this work indicated that the ratios
of IFN-γ to Il-4 in Ag85a-Cfp10, Ag85a-Tb10.4, Mtb32C-HBHA,
and co-administration with vaccines were 1.8, 27.31, 15, and
36.18, respectively. These results suggest that the combina-
tion of these three DNA vaccines is more potent than each
one alone in stimulating immune responses (9, 13-15). In
fact, these results were obtained in the absence of any adju-
vants; therefore, continuing such experiments and analyz-
ing different aspects of these new antigens will be hopeful.
This study showed that IFN-γ production by the three
chimeric DNA vaccines was the most desirable outcome
that eventually led to the induction of cellular responses.
In addition, the induction of cytokines including IFN-γ,
IL-12, and TGF-β was precisely correlated with enhanced
BCG-mediated protective immunity. Consistent with pre-
vious studies, the ratio of IFN-γ to IL-4 in the BCG-vaccine
group (BCG for priming and DNA vaccines for boosting)
was higher than the ratio in the vaccine group, indicat-
ing that the cell-mediated immunity was more stimulated
than humoral immunity. Our results showed that these
chimeric DNA vaccines could enhance the effectiveness
of the BCG vaccine and they could be used as boosters
(39). In the present study, the co-administration of the
three DNA vaccines encoding several immunodominant
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antigens were observed for investigating the efficacy of
the currently used TB vaccine, BCG. However, the protec-
tive properties of these DNA constructs and their thera-
peutic effects remain to be examined in detail in future
studies. Finally, the present results suggest that Mtb32C-
HBHA, Ag85a-Cfp10, Ag85a-Tb10.4 fusion proteins could po-
tentially be used as promising candidate antigens for fu-
ture TB vaccine development.
4.1. Study Limitations
Because of limitations in the animal isolator, the ani-
mal challenge test was not performed; therefore, the levels
of modulatory cytokines in the lung of mice were not mea-
sured. Humoral immunity is not effective against intracel-
lular pathogens like M. tuberculosis; therefore, the levels of
antibodies in the serum of immunized mice were not as-
sessed. Furthermore, the generation of effector-memory T
cell and the therapeutic properties of constructed vectors
were not evaluated. Bioinformatics analysis of these new
fusion antigens will be helpful in the identification of re-
lated B cell and T cell epitopes.
4.2. Conclusions
The most effective immune response against TB is cell-
mediated immunity; hence, drawing attention to this
point is very critical in vaccine development. Recent stud-
ies have indicated that the prime-boost strategy is a suit-
able way to access this goal. Based on the obtained re-
sults, the immunization of mice primed with BCG and then
boosted with mycobacterial immunodominant antigens
can induce effectively Th1 cytokines.
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